Literature DB >> 17131317

CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study.

Domenico Palli1, Giovanna Masala, Giuseppe Del Giudice, Mario Plebani, Daniela Basso, Duccio Berti, Mattijs E Numans, Mattijs E Numans, Marco Ceroti, Petra H M Peeters, H Bas Bueno de Mesquita, Frederike L Buchner, Francoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, Vittorio Krogh, Calogero Saieva, Paolo Vineis, Salvatore Panico, Rosario Tumino, Olof Nyrén, Henrik Simán, Goran Berglund, Goran Hallmans, Maria-Jose Sanchez, Nerea Larrãnaga, Aurelio Barricarte, Carmen Navarro, Jose R Quiros, Tim Key, Naomi Allen, Sheila Bingham, Kay Tee Khaw, Heiner Boeing, Cornelia Weikert, Jakob Linseisen, Gabriele Nagel, Kim Overvad, Reimar W Thomsen, Anne Tjonneland, Anja Olsen, Antonia Trichoupoulou, Dimitrios Trichopoulos, Athina Arvaniti, Guillem Pera, Rudolf Kaaks, Mazda Jenab, Pietro Ferrari, Gabriella Nesi, Fatima Carneiro, Elio Riboli, Carlos A Gonzalez.   

Abstract

Helicobacter pylori (H. pylori), atrophic gastritis, dietary and life-style factors have been associated with gastric cancer (GC). These factors have been evaluated in a large case-control study nested in the European Prospective Investigation into Cancer and Nutrition carried out in 9 countries, including the Mediterranean area. Participants, enrolled in 1992-1998, provided life-style and dietary information and a blood sample (360,000; mean follow-up: 6.1 years). For 233 GC cases diagnosed after enrolment and their 910 controls individually-matched by center, gender, age and blood donation date H. pylori antibodies (antilysate and antiCagA) and plasma Pepsinogen A (PGA) were measured by ELISA methods. Severe chronic atrophic gastritis (SCAG) was defined as PGA circulating levels <22 microg/l. Overall, in a conditional logistic regression analysis adjusted for education, smoke, weight and consumption of total vegetables, fruit, red and preserved meat, H. pylori seropositivity was associated with GC risk. Subjects showing only antibodies anti-H. pylori lysate, however, were not at increased risk, while those with antiCagA antibodies had a 3.4-fold increased risk. Overall, the odds ratio associated with SCAG was 3.3 (95% CI 2.2-5.2). According to site, the risk of noncardia GC associated with CagA seropositivity showed a further increase (OR 6.5; 95% CI 3.3-12.6); on the other hand, a ten-fold increased risk of cardia GC was associated with SCAG (OR 11.0; 95% CI 3.0-40.9). These results support the causal relationship between H. pylori CagA+ strains infection, and GC in these European populations even after taking into account dietary habits. This association was limited to distal GC, while serologically defined SCAG was strongly associated with cardia GC, thus suggesting a divergent risk pattern for these 2 sites.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17131317     DOI: 10.1002/ijc.22435

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

Review 1.  Helicobacter pylori and gastric cancer.

Authors:  Hidekazu Suzuki; Eisuke Iwasaki; Toshifumi Hibi
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

Review 2.  Role of Helicobacter pylori infection in autoimmune systemic rheumatic diseases.

Authors:  Mislav Radić
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 3.  Gastric carcinogenesis.

Authors:  Jan Bornschein; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2011-05-25       Impact factor: 3.445

4.  ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study.

Authors:  Harvey A Risch; Herbert Yu; Lingeng Lu; Mark S Kidd
Journal:  J Natl Cancer Inst       Date:  2010-02-24       Impact factor: 13.506

5.  Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries.

Authors:  Seiji Shiota; Osamu Matsunari; Masahide Watada; Yoshio Yamaoka
Journal:  Future Microbiol       Date:  2010-12       Impact factor: 3.165

6.  Evaluation of a commercial immunoblot, Helicoblot 2.1, for diagnosis of Helicobacter pylori infection.

Authors:  Lea Veijola; Aino Oksanen; Pentti Sipponen; Hilpi Rautelin
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

7.  Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.

Authors:  Chika Kusano; Takuji Gotoda; Sho Suzuki; Hisatomo Ikehara; Mitsuhiko Moriyama
Journal:  J Gastroenterol       Date:  2017-11-07       Impact factor: 7.527

8.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

Review 9.  Comparative genomics of Helicobacter pylori.

Authors:  Quan-Jiang Dong; Qing Wang; Ying-Nin Xin; Ni Li; Shi-Ying Xuan
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

10.  Endoscopic and histopathologic findings associated with H. pylori infection in very young children.

Authors:  Engin Tutar; Deniz Ertem; Esin Kotiloglu Karaa; Ender Pehlivanoglu
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.